Menopause is defined as permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of amenorrhea without any other obvious cause. Over the years, the discourse surrounding the Climacteric was mainly elicited as a “disease of the castrates”, as opposed to the feminist views. There has been a large feminist contribution to both the debate of contraception and menopause in the last few years. Over the years, menopause has been treated in a uniform fashion, as a disease, excluding the different circumstances and lived experiences that patients go through during this sensitive period. Every primary care provider should be familiar with the menopausal process and be able to provide adequate care for these women, respecting patient's autonomy and decision making. A brief historical of menopause and hormone replacement therapy (HRT) will be reviewed in this paper. We will also discuss the different views of the menopausal discourse as well as the benefits and risks, compliance rates and reasons for discontinuation of HRT.
OddensBJBouletMJLehertPet al.Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries. Maturitas1992; 15: 171–181.
2.
BellSE. Changing ideas: the medicalization of menopause. Soc Sci Med1987; 24: 535–542.
3.
PriorJC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev1998; 19: 397–428.
4.
BowlesC. The menopausal experience: sociocultural influences and theoretical models, London: The Analytic Press, 1990.
5.
WilsonRAWilsonTA. The fate of the nontreated postmenopausal woman: a plea for the maintenance of adequate estrogen from puberty to the grave. J Am Geriatr Soc1963; 11: 347–362.
6.
FormanekRE. The meanings of menopause: historical, medical, and clinical perspectives, London: The Analytic Press, 1990.
7.
YoungRMayHMurphySet al.Rates of bone loss in peri- and postmenopausal women: a 4 year, prospective, population-based study. Clin Sci (Lond)1996; 91: 307–312.
8.
ConeyS. The menopause industry, CA: Hunter House, 1994.
9.
Doress-WortersPBSiegalDL. The new ourselves, growing older: women aging with knowledge and power, New York: Simon and Schuster, 1994.
10.
KaufertPL. Methodological issues in menopause research. Ann N Y Acad Sci1990; 592: 114–122. discussion 23–33.
11.
EspeyE. Feminism and the moral imperative for contraception. Obstet Gynecol2015; 126: 396–400.
12.
GuilleminMN. Managing menopause: a critical feminist engagement. Scand J Public Health1999; 27: 273–278.
13.
HarrisMT. Aging women's journey toward wholeness: new visions and directions. Health Care Women Int2008; 29: 962–979.
14.
BellSE. Sociological perspectives on the medicalization of menopause. Ann N Y Acad Sci1990; 592: 173–178. discussion 85–92.
15.
MansonJEChlebowskiRTStefanickMLet al.Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA2013; 310: 1353–1368.
16.
HodisHNMackWJHendersonVWet al.Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med2016; 374: 1221–1231.
17.
SalpeterSRWalshJMGreyberESalpeterEE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med2006; 21(4): 363–6.
18.
MansonJEAllisonMARossouwJEet al.Estrogen therapy and coronary-artery calcification. N Engl J Med2007; 356: 2591–2602.
19.
HarmanSMBlackDMNaftolinFet al.Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med2014; 161: 249–260.
20.
MarjoribanksJFarquharCRobertsHet al.Trial does not change the conclusions of Cochrane review of long term hormone therapy for perimenopausal and postmenopausal women. BMJ2012; 345: e8141. author reply e64.
21.
BoardmanHMHartleyLEisingaAet al.Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev2015; 3: CD002229.
22.
SchierbeckLLRejnmarkLToftengCLet al.Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012; 345: e6409.
23.
RossouwJEPrenticeRLMansonJEet al.Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007; 297: 1465–1477.
24.
RavnikarVA. Compliance with hormone therapy. Am J Obstet Gynecol1987; 156: 1332–1334.
25.
CanoA. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas1994; 20: 91–99.
26.
ShelleyJMSmithAMDudleyEet al.Use of hormone replacement therapy by Melbourne women. Aust J Public Health1995; 19: 387–392.
27.
SpragueBLTrentham-DietzACroninKA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol2012; 120: 595–603.
28.
OddensBJBouletMJLehertPet al.A study on the use of medication for climacteric complaints in western Europe – II. Maturitas1994; 19: 1–12.
29.
SogaardAJTollanABerntsenGKet al.Hormone replacement therapy: knowledge, attitudes, self-reported use – and sales figures in Nordic women. Maturitas2000; 35: 201–214.
30.
StadbergEMattssonLAMilsomI. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Acta Obstet Gynecol Scand1997; 76: 442–448.
31.
OlesenCSteffensenFHSorensenHTet al.Low use of long-term hormone replacement therapy in Denmark. Br J Clin Pharmacol1999; 47: 323–328.
32.
LoppieCKeddyB. A feminist analysis of the menopause discourse. Contemp Nurse2002; 12: 92–99.
33.
MurtaghMJHepworthJ. Feminist ethics and menopause: autonomy and decision-making in primary medical care. Soc Sci Med2003; 56: 1643–1652.
34.
LyonsACGriffinC. Managing menopause: a qualitative analysis of self-help literature for women at midlife. Soc Sci Med2003; 56: 1629–1642.
